Aug 15
Opportunity
Clinical trial participants will likely not feel engaged with the clinical trial if they are not informed about what matters to them (e.g., trial progress) at an appropriate frequency. Providing relevant information through a method that meets their needs and preferences could improve participant engagement, compliance and retention. Value can be gained where participants can choose how and when they receive communications.
Considerations to Help Action the Opportunity
- Partner with patient organizations and sites to identify the types of information that participants would like (e.g., gratitude, trial progress) and the preferred method and frequency for sharing of information
- Define the settings (e.g., in-person or self-reviewed), mediums (e.g., written, audio or visual), delivery methods (e.g., paper, email, WhatsApp / text, portal / app), preferred language, and frequency (e.g., weekly, monthly, annually) for the communications
- Utilize the settings, mediums and methods that work for the participant population and ideally provide multiple options to suit the spectrum of participant needs (e.g., to account for country or age preferences)
- Define design considerations that factor in the participant or site needs, such as font sizes, consistent formatting and ‘branding’
- Develop a participant communication plan that captures participant preferences and delivers communications accordingly
- Define the timing and requirements of obtaining Ethics Committee (EC) approval (e.g., submit any templates at the start of the study outlining the type of communication planned) on participant facing materials and the method of delivery
Value and Potential Benefits
- Increases understanding and engagement in the trial if participants receive communications that are relevant to them in a preferred format and frequency
- Allows participants to have the information they require, while avoiding overwhelming or burdensome communications
- Allows participants to feel appreciated and valued for their involvement in the study
- Potentially increases trial participant retention (avoid drop-outs) and compliance (higher motivation)
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
